

WHODrug Global September 2021 version now available

The September 2021 version of WHODrug Global is now available. It can be downloaded from the WHODrug Download Area (by designated delivery contacts), and accessed via WHODrug Insight, both linked from the [UMC website](#). The September 2021 version of the WHODrug Global dictionary contains over **565,000 drug names** from 167 countries.


COVID-19 update

Uppsala Monitoring Centre (UMC) is continually monitoring the COVID-19 situation. Below, we summarise the status of our current operations, and also report on new COVID-19 related initiatives:

- All UMC's WHODrug operations and services continue without disruption.

- UMC is continually updating WHODrug with drug information from all over the world, and COVID-19 vaccines and other related medicinal products are prioritised in this work. To access drug information updated on a daily basis, WHODrug users are recommended to make use of the 'Upcoming data' version, available in WHODrug Insight.

- UMC continues to strengthen the virtual event programme for WHODrug users, as the possibility to host face-to-face events around the world still is uncertain. As well as monthly webinars, UMC is planning several User Group webcasts for 2021; for more information see below.



Increased search capability and efficiency in WHODrug Insight

WHODrug Insight is a go-to application in the daily work of many WHODrug users. After carefully listening to users' needs, we have created new search and viewing functionalities in WHODrug Insight. The new features are:

- Free text filters, to narrow down the search result based on MAH, pharmaceutical form and/or strength information.

- Improved scroll down feature for the search result.


- Possibility to highlight ingredient differences between selected drug names in the search result. This new feature may be used while investigating differences between similar product names, thereby speeding up coding decisions.

- Search functionality for active moiety variations. This feature enables a "contains search" based on the name selected in the active ingredient field. For example, by selecting the active ingredient 'Digoxin', a total of five active moiety variations are retrieved: 'Acetyldigoxin', 'Beta-acetyldigoxin', 'Digoxin', 'Digoxin-specific antibody fragments' and 'Metildigoxin'. The list of active moiety variations obtained can be reviewed before being used to perform conventional searches. This advanced search option specifically supports the creation of Customised Drug Groupings (CDGs).

For questions about these, or for any feedback, please contact WHODrug@who-umc.org.

WHODrug User Group meetings 2021

After several successful events during the first half of the year, we are happy to announce the date for our next **WHODrug User Group webcast: Wednesday, 27 October 2021**. It will be a special global virtual conference with focus on topics relevant to WHODrug users all around the world. For your convenience, it will be hosted in two different time slots, to accommodate users from multiple time zones. Stay tuned for more information.



Additional WHODrug virtual events are coming in the second part of 2021. All these events will be virtual and free of charge to users working at organisations with a valid WHODrug licence.

These are the events planned so far:

- **WHODrug Global event**, 27 October 2021 at 09:00 and 17:00 CEST – hosted on OnAIR
- **Republic of Korea**, end of November 2021 – hosted on GoToWebinar
- **Japan**, 9 December 2021 – hosted on OnAIR

[Read more and sign up](#)


Increased coverage of generic synonym information in WHODrug Global Chinese

WHODrug Global Chinese is a Chinese language version of WHODrug Global. For each release, WHODrug Global Chinese is updated with new drug information in Chinese language, to support drug coding and regulatory submissions.

For the September 2021 version, a specific focus area has been to increase the coverage of generic synonym names in Chinese language. For more information, or to provide feedback, please [contact UMC](#).

WHODrug Koda: retrained machine learning model – and more

WHODrug Koda, UMC's drug coding engine, is built on advanced coding algorithms and artificial intelligence (AI) by machine learning (ML). For the September 2021 release of WHODrug Global, as for all releases, the ML model has been retrained, partly based on feedback from WHODrug Koda users worldwide, improving the performance of WHODrug Koda.



Based on user requests, ATC text information has been introduced in the export file from the WHODrug Koda web application. The ATC texts are available in separate columns.

All WHODrug users are entitled to assess and evaluate WHODrug Koda free of charge via a trial web application, for a limited number of terms. To fully support users looking to evaluate WHODrug Koda via the trial web application, the 'Coding path' information, previously only available for the full version of WHODrug Koda, is now also available in the trial application. The coding path describes the reasoning behind the coding predictions from WHODrug Koda.

Access the WHODrug Koda trial application, or [contact UMC](#) for support or a customised demonstration.

[Try WHODrug Koda](#)

Next WHODrug monthly webinar

Sign up now for our **What's New in WHODrug Global webinar**, scheduled for **Tuesday, 14 September 2021** and available at two time slots, 09:00 and 17:00 CEST. UMC staff will be covering the latest COVID-19 related WHODrug updates, the global vaccines initiative, and the latest features available to WHODrug Koda users, among other topics. WHODrug users are encouraged to submit questions in advance to whodrug@who-umc.org.

[Register here](#)

Did you know...

...that from June 2021, the Republic of Korea's Ministry of Food and Drug Safety (MFDS) accepts E2B(R3) as a reporting standard for adverse drug reaction (ADR) cases? **WHODrug Link Korea**, released for the first time in March 2021, facilitates the identification of the local Korean drug identifiers needed for E2B(R3) compliant submissions for domestic cases. [Contact UMC](#) for more information on how to access WHODrug Link Korea.

[Read more](#)



Copyright © 2021 Uppsala Monitoring Centre, All rights reserved.
This e-mail informs you about WHODrug related products or services provided by UMC

Our mailing address is:
Uppsala Monitoring Centre
P.O. Box 1051
Visits and deliveries to Bredgränd 7, 753 22
Uppsala SE-751 40
Sweden

For information on how we treat your personal data, please read our [Privacy Policy](#).

Want to change how you receive these emails?
You can [unsubscribe from this list](#)